Darovasertib (IDE196)
Uveal Melanoma (GNAQ/GNA11 mutations)
Phase 2/3Active
Key Facts
About IDEAYA Biosciences
IDEAYA Biosciences is a precision medicine oncology company founded in 2016 with a mission to develop transformative, biomarker-selected cancer therapies. It has established itself as a leader in the field of synthetic lethality, building a robust clinical-stage pipeline through internal discovery and strategic collaborations with major pharmaceutical partners like GSK, Pfizer, and Gilead. The company's strategy focuses on exploiting specific genetic vulnerabilities in cancer cells to achieve a therapeutic window, with its most advanced programs targeting MTAP-deleted solid tumors, GNAQ/GNA11-mutant cancers, and homologous recombination deficient tumors.
View full company profile